DRTSHealthcare · BiotechnologyDRTS Stock Forecast: Alpha Tau Medical Ltd. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Alpha Tau Medical Ltd. hold a median 12-month price target of $16 — +12.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 15 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
DRTS stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Alpha Tau Medical Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (100): The shares have been drifting up relative to others.
Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
DRTS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DRTS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +12.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $15 → $16 |
| 22 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 16 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 4 June 2026 | Barclays | Maintains | Overweight | — |
| 4 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 May 2026 | Barclays | Initiates | Overweight | — |
| 20 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 May 2026 | Piper Sandler | Maintains | Neutral | — |
| 12 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 May 2026 | Ladenburg Thalmann | Maintains | Buy | — |
| 11 Mar 2026 | Citigroup | Maintains | Buy | — |
| 10 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Mar 2026 | Piper Sandler | Downgrade | Neutral | — |
| 24 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Dec 2025 | Citigroup | Maintains | Buy | — |
| 24 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DRTS appears on the weeks it earns a place.
DRTS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Alpha Tau Medical Ltd. (DRTS) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −26.9×
- Price / sales
- —
- Price / book
- 18.5×
- EV / EBITDA
- −25.2×
Cheaper than 97% of US stocks
Cheaper than 6% of US stocks
Cheaper than 90% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −141.7%
- Return on assets
- −25.7%
- Dividend yield
- —
Higher than 9% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
DRTS vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alpha Tau Medical Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about DRTS stock
What is the DRTS stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Alpha Tau Medical Ltd. have a median 12-month price target of $16, with estimates ranging from $8 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DRTS stock a buy right now?
Of the 5 analysts covering Alpha Tau Medical Ltd., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alpha Tau Medical Ltd. 17 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DRTS?
As at 15 Aug 2026, Alpha Tau Medical Ltd. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).
Will DRTS stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +12.3% from the last close, and Ticker Nerd's factor model ranks Alpha Tau Medical Ltd. 17 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DRTS stock forecast for 2030?
No analyst covering Alpha Tau Medical Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $17 over the next 12 months.
How has DRTS stock performed over the past year?
Alpha Tau Medical Ltd. returned +345.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Alpha Tau Medical Ltd. do?
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on developing and commercializing Alpha DaRT, a localized alpha-radiation therapy for solid tumors.
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on developing and commercializing Alpha DaRT, a localized alpha-radiation therapy for solid tumors. The company’s platform is designed to deliver alpha-emitting radiation directly within cancerous tissue, supporting treatment approaches that target tumors while limiting exposure to surrounding healthy tissue. Alpha Tau Medical Ltd. is advancing applications across multiple oncology areas, including skin, oral, pancreatic, prostate, lung, liver, and breast cancers. Its work spans research, clinical development, and potential commercialization, making it a specialist in precision cancer treatment technologies. Headquartered in Jerusalem, Israel, Alpha Tau Medical Ltd. operates in the healthcare and biotechnology sectors and plays a role in the broader market for innovative radiation-based oncology solutions.
CEO Mr. Uzi Sofer · 121 employees · Israel · https://www.alphatau.com